問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

CHANGHUA CHRISTIAN HOSPITAL

List

840Cases

2012-08-31 - 2020-04-01

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2007-03-01 - 2008-12-31

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-11-01 - 2019-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2012-12-01 - 2019-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2019-11-01 - 2025-02-28

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2009-08-01 - 2012-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2016-12-01 - 2018-12-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2008-08-01 - 2021-07-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2017-03-15 - 2024-12-31

Phase III

Completed
A Phase 3, Randomized, Open-Label, Active-Controlled Study of ALXN1210 Versus Eculizumab in Complement Inhibitor-Naïve Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Condition/Disease

    Paroxysmal Nocturnal Hemoglobinuria (PNH)

  • Test Drug

    ALXN1210

Participate Sites
7Sites

Terminated6Sites

2025-05-01 - 2029-06-30

Phase III

Active
EASi-HF reduced – A Phase III double-blind, randomised, parallel-group superiority trial to evaluate efficacy and safety of the combined use of oral vicadrostat (BI 690517) and empagliflozin compared with placebo and empagliflozin in participants with symptomatic chronic heart failure (HF: NYHA II-IV) and left ventricular ejection fraction (LVEF) < 40%

  • Condition/Disease

    Chronic heart failure (HF: NYHA Class II–IV) with left ventricular ejection fraction (LVEF) < 40%.

  • Test Drug

    empagliflozin vicadrostat (BI 690517)

Participate Sites
8Sites

Recruiting8Sites

1 22 23 24 25 26 84
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB